instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the dosage of drug 'LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN'? | Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report.
BACKGROUND
Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, thrombocytopenia, and renal involvement. Complement-mediated atypical HUS (aHUS) is a ... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 34084691 | 19,938,655 | 2021 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report.
BACKGROUND
Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, thrombocytopenia, and renal involvement. Complement-mediated atypical HUS (aHUS) is a ... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 34084691 | 19,938,655 | 2021 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report.
BACKGROUND
Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, thrombocytopenia, and renal involvement. Complement-mediated atypical HUS (aHUS) is a ... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 34084691 | 19,938,655 | 2021 |
What was the dosage of drug 'TACROLIMUS'? | Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report.
BACKGROUND
Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, thrombocytopenia, and renal involvement. Complement-mediated atypical HUS (aHUS) is a ... | UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 34084691 | 19,938,655 | 2021 |
What was the outcome of reaction 'Disease recurrence'? | Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report.
BACKGROUND
Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, thrombocytopenia, and renal involvement. Complement-mediated atypical HUS (aHUS) is a ... | Recovered | ReactionOutcome | CC BY | 34084691 | 19,938,655 | 2021 |
What was the outcome of reaction 'Thrombotic microangiopathy'? | Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report.
BACKGROUND
Hemolytic uremic syndrome (HUS) is a rare disease characterized by microangiopathic hemolysis, thrombocytopenia, and renal involvement. Complement-mediated atypical HUS (aHUS) is a ... | Recovered | ReactionOutcome | CC BY | 34084691 | 19,938,655 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chills'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypotension'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oral pain'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory depression'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Restlessness'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Seizure'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tremor'. | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | LEVETIRACETAM | DrugsGivenReaction | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
What was the dosage of drug 'LEVETIRACETAM'? | Effectiveness and adverse drug reactions of levetiracetam and midazolam in refractory neonatal seizure: A cross-sectional comparative study.
BACKGROUND
Neonatal seizure (NS) reflects serious underlying brain injury, requiring immediate evaluation and early treatment. In neonates, phenobarbitone and phenytoin are used p... | UNKNOWN DOSE | DrugDosageText | CC BY-NC-SA | 34084865 | 19,473,141 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ocular hypertension'. | Intraocular Pressure Changes after Intravitreal Bevacizumab or Ranibizumab Injection: A Retrospective Study.
To determine intraocular pressure (IOP) changes after intravitreal bevacizumab or ranibizumab injection administered for various retinal disorders.
A retrospective chart review of 796 eyes of 574 patients receiv... | RANIBIZUMAB | DrugsGivenReaction | CC BY-NC-SA | 34084950 | 19,981,954 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chorioretinopathy'. | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | DEXAMETHASONE | DrugsGivenReaction | CC BY-NC-SA | 34084962 | 19,591,718 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | DEXAMETHASONE | DrugsGivenReaction | CC BY-NC-SA | 34084962 | 19,565,588 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Detachment of retinal pigment epithelium'. | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | DEXAMETHASONE | DrugsGivenReaction | CC BY-NC-SA | 34084962 | 19,565,588 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | DEXAMETHASONE | DrugsGivenReaction | CC BY-NC-SA | 34084962 | 19,591,718 | 2021 |
What was the administration route of drug 'DEXAMETHASONE'? | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-SA | 34084962 | 19,565,588 | 2021 |
What was the dosage of drug 'DEXAMETHASONE'? | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | 8 mg (milligrams). | DrugDosage | CC BY-NC-SA | 34084962 | 19,565,588 | 2021 |
What was the outcome of reaction 'Chorioretinopathy'? | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | Recovered | ReactionOutcome | CC BY-NC-SA | 34084962 | 19,591,718 | 2021 |
What was the outcome of reaction 'Condition aggravated'? | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | Recovered | ReactionOutcome | CC BY-NC-SA | 34084962 | 19,565,588 | 2021 |
What was the outcome of reaction 'Detachment of retinal pigment epithelium'? | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | Recovered | ReactionOutcome | CC BY-NC-SA | 34084962 | 19,565,588 | 2021 |
What was the outcome of reaction 'Disease recurrence'? | Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration.
To describe a case of pachychoroid disease most compatible with central serous chorioretinopathy (CSC) presented with a large relapsing retinal pigment epithelial detachment (PED) associated with only a small amount of subretinal... | Recovered | ReactionOutcome | CC BY-NC-SA | 34084962 | 19,591,718 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bundle branch block left'. | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | FLECAINIDE, HERBALS, WARFARIN | DrugsGivenReaction | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug interaction'. | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | FLECAINIDE, HERBALS, WARFARIN | DrugsGivenReaction | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Herbal interaction'. | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | FLECAINIDE, HERBALS, WARFARIN | DrugsGivenReaction | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Syncope'. | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | FLECAINIDE ACETATE | DrugsGivenReaction | CC BY-NC | 34084998 | 19,593,204 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tachycardia'. | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | FLECAINIDE, HERBALS, WARFARIN | DrugsGivenReaction | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | FLECAINIDE ACETATE | DrugsGivenReaction | CC BY-NC | 34084998 | 19,593,204 | 2021-06 |
What was the dosage of drug 'HERBALS'? | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | 1?2 GLASSES PER DAY | DrugDosageText | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
What was the outcome of reaction 'Bundle branch block left'? | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | Recovered | ReactionOutcome | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
What was the outcome of reaction 'Drug interaction'? | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | Recovered | ReactionOutcome | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
What was the outcome of reaction 'Herbal interaction'? | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | Recovered | ReactionOutcome | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
What was the outcome of reaction 'Tachycardia'? | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | Recovered | ReactionOutcome | CC BY-NC | 34084998 | 19,456,624 | 2021-06 |
What was the outcome of reaction 'Toxicity to various agents'? | Flecainide toxicity associated with the use of goji berries: a case report.
Goji berries (GB), usually marketed as a 'superfruit', are a widely used herbal supplement. As with other herbal remedies, the use of GB might be associated with herb-drug interactions, increasing plasma levels of other drugs and causing advers... | Recovered | ReactionOutcome | CC BY-NC | 34084998 | 19,593,204 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatotoxicity'. | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | FLUOROURACIL, GRANULOCYTE COLONY-STIMULATING FACTOR NOS, IRINOTECAN HYDROCHLORIDE, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the administration route of drug 'FLUOROURACIL'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the administration route of drug 'IRINOTECAN HYDROCHLORIDE'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the administration route of drug 'LEUCOVORIN CALCIUM'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the administration route of drug 'OXALIPLATIN'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the dosage of drug 'FLUOROURACIL'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | 2400 MG/M2, CYCLIC (OVER 46 HOURS, INFUSION OVER 46 HOURS REPEATED EVERY 2 WEEKS) | DrugDosageText | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the dosage of drug 'GRANULOCYTE COLONY-STIMULATING FACTOR NOS'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | UNK (DAYS 4, 6, AND 8 WITH EACH CYCLE) | DrugDosageText | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the dosage of drug 'IRINOTECAN HYDROCHLORIDE'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | 150 MG/M2, CYCLIC (OVER 90 MINUTES ON DAY 1) | DrugDosageText | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the dosage of drug 'LEUCOVORIN CALCIUM'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | 400 MG/M2, CYCLIC (OVER 90 MINUTES ON DAY 1) | DrugDosageText | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
What was the dosage of drug 'OXALIPLATIN'? | Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.
For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, a... | 85 MG/M2, CYCLIC (OVER 2 HOURS) | DrugDosageText | CC BY-NC-ND | 34086477 | 19,481,159 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemorrhage'. | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | EDOXABAN TOSYLATE, EPERISONE HYDROCHLORIDE, ESOMEPRAZOLE MAGNESIUM, REBAMIPIDE, ZALTOPROFEN | DrugsGivenReaction | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Interstitial lung disease'. | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | EDOXABAN TOSYLATE, EPERISONE HYDROCHLORIDE, ESOMEPRAZOLE MAGNESIUM, REBAMIPIDE, ZALTOPROFEN | DrugsGivenReaction | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the administration route of drug 'EPERISONE HYDROCHLORIDE'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | Oral | DrugAdministrationRoute | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the administration route of drug 'ESOMEPRAZOLE MAGNESIUM'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | Oral | DrugAdministrationRoute | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the administration route of drug 'REBAMIPIDE'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | Oral | DrugAdministrationRoute | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the administration route of drug 'ZALTOPROFEN'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | Oral | DrugAdministrationRoute | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the dosage of drug 'EPERISONE HYDROCHLORIDE'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | 300MG/DAY | DrugDosageText | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the dosage of drug 'ESOMEPRAZOLE MAGNESIUM'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | 20MG/DAY | DrugDosageText | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the dosage of drug 'REBAMIPIDE'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | 300MG/DAY | DrugDosageText | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the dosage of drug 'ZALTOPROFEN'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | 160MG/DAY | DrugDosageText | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
What was the outcome of reaction 'Interstitial lung disease'? | Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
BACKGROUND
Drug-induced pneumonia (d-pneumonia) and bacterial pneumonia (b-pneumonia) are often difficult to differentiate; therefore, this study examined the possibility of differentiating them using serum biom... | Recovered | ReactionOutcome | CC BY | 34088359 | 20,432,070 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal pain'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bacteraemia'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Coagulopathy'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal perforation'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Normocytic anaemia'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Purpura'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Shock'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Splenomegaly'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Staphylococcal bacteraemia'. | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | CEFEPIME HYDROCHLORIDE, FORMOTEROL FUMARATE, GANCICLOVIR, MEROPENEM, PHYTONADIONE | DrugsGivenReaction | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
What is the weight of the patient? | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | 51 kg. | Weight | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
What was the dosage of drug 'GANCICLOVIR'? | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | 5 MG/KG, BID, SINCE DAY 27 FROM HOSPITALISATION | DrugDosageText | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
What was the dosage of drug 'MEROPENEM'? | Multiple thrombosis associated with Cytomegalovirus enterocolitis in an immunocompetent patient: a case report.
BACKGROUND
Cytomegalovirus (CMV) is reported to have thrombogenic characteristics that activate factor X in vitro and stimulate the production of factor VIII and von Willebrand factor (vWF). Thrombosis associ... | 2 G, DAILY | DrugDosageText | CC BY | 34090366 | 19,445,650 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Laryngeal stenosis'. | Pyoderma gangrenosum-like ulceration as a presenting feature of pediatric granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is an anti-neutrophilic cytoplasmic antibody-associated vasculitis affecting small to medium-sized vessels and involves most commonly the kidneys and the respirat... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34090470 | 19,430,255 | 2021-06-05 |
What was the administration route of drug 'CYCLOPHOSPHAMIDE'? | Pyoderma gangrenosum-like ulceration as a presenting feature of pediatric granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is an anti-neutrophilic cytoplasmic antibody-associated vasculitis affecting small to medium-sized vessels and involves most commonly the kidneys and the respirat... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34090470 | 19,430,255 | 2021-06-05 |
What was the administration route of drug 'PREDNISONE'? | Pyoderma gangrenosum-like ulceration as a presenting feature of pediatric granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is an anti-neutrophilic cytoplasmic antibody-associated vasculitis affecting small to medium-sized vessels and involves most commonly the kidneys and the respirat... | Oral | DrugAdministrationRoute | CC BY | 34090470 | 19,430,255 | 2021-06-05 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Pyoderma gangrenosum-like ulceration as a presenting feature of pediatric granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is an anti-neutrophilic cytoplasmic antibody-associated vasculitis affecting small to medium-sized vessels and involves most commonly the kidneys and the respirat... | MONTHLY | DrugDosageText | CC BY | 34090470 | 19,430,255 | 2021-06-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19 pneumonia'. | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | ATOVAQUONE, LEVETIRACETAM, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34091704 | 19,584,177 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immunosuppression'. | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34091704 | 19,476,369 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'No adverse event'. | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | LEVETIRACETAM, METHOTREXATE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34091704 | 20,500,039 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | ATOVAQUONE, LEVETIRACETAM, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34091704 | 19,584,177 | 2021-08 |
What was the administration route of drug 'PREDNISONE'? | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | Oral | DrugAdministrationRoute | CC BY | 34091704 | 19,584,177 | 2021-08 |
What was the dosage of drug 'COVID-19 CONVALESCENT PLASMA'? | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | UNK, (RECEIVED TWO UNITS) | DrugDosageText | CC BY | 34091704 | 20,876,588 | 2021-08 |
What was the dosage of drug 'METHOTREXATE'? | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | UNKNOWN DOSE | DrugDosageText | CC BY | 34091704 | 20,500,039 | 2021-08 |
What was the outcome of reaction 'COVID-19 pneumonia'? | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | Recovered | ReactionOutcome | CC BY | 34091704 | 19,584,177 | 2021-08 |
What was the outcome of reaction 'COVID-19'? | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | Recovered | ReactionOutcome | CC BY | 34091704 | 19,584,177 | 2021-08 |
What was the outcome of reaction 'Sepsis'? | COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
A 77-year-old man with past medical history of granulomatosis with polyangiitis (GPA) on rituximab and prednisone, presented to the hospital with worsening cough and shortness of breath. He had tested positive for sev... | Recovered | ReactionOutcome | CC BY | 34091704 | 19,584,177 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy.
We present a female patient in her early twenties with global development delay, progressive ataxia, epilepsy, and myoclonus caused by a stop mutation in the SEMA6B gene. Truncating DNA variants located in the last exon of SEMA6B have ... | LEVETIRACETAM, PHENOBARBITAL | DrugsGivenReaction | CC BY-NC-ND | 34092044 | 19,958,537 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urinary incontinence'. | Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy.
We present a female patient in her early twenties with global development delay, progressive ataxia, epilepsy, and myoclonus caused by a stop mutation in the SEMA6B gene. Truncating DNA variants located in the last exon of SEMA6B have ... | LEVETIRACETAM, PHENOBARBITAL | DrugsGivenReaction | CC BY-NC-ND | 34092044 | 19,958,537 | 2021-07 |
What was the outcome of reaction 'Urinary incontinence'? | Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy.
We present a female patient in her early twenties with global development delay, progressive ataxia, epilepsy, and myoclonus caused by a stop mutation in the SEMA6B gene. Truncating DNA variants located in the last exon of SEMA6B have ... | Recovering | ReactionOutcome | CC BY-NC-ND | 34092044 | 19,958,537 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute kidney injury'. | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | BEVACIZUMAB, CARBOPLATIN, PEMETREXED | DrugsGivenReaction | CC BY-NC-ND | 34092725 | 20,203,291 | 2021-11-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adrenocorticotropic hormone deficiency'. | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | BEVACIZUMAB, CARBOPLATIN, NIVOLUMAB, PEMETREXED | DrugsGivenReaction | CC BY-NC-ND | 34092725 | 20,195,554 | 2021-11-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to adrenals'. | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | BEVACIZUMAB, CARBOPLATIN, PEMETREXED | DrugsGivenReaction | CC BY-NC-ND | 34092725 | 20,203,291 | 2021-11-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to bladder'. | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | BEVACIZUMAB, CARBOPLATIN, PEMETREXED | DrugsGivenReaction | CC BY-NC-ND | 34092725 | 20,203,291 | 2021-11-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to lymph nodes'. | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | BEVACIZUMAB, CARBOPLATIN, PEMETREXED | DrugsGivenReaction | CC BY-NC-ND | 34092725 | 20,203,291 | 2021-11-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm progression'. | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | BEVACIZUMAB, CARBOPLATIN, PEMETREXED | DrugsGivenReaction | CC BY-NC-ND | 34092725 | 20,178,710 | 2021-11-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Primary adrenal insufficiency'. | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | BEVACIZUMAB, CARBOPLATIN, NIVOLUMAB, PEMETREXED | DrugsGivenReaction | CC BY-NC-ND | 34092725 | 20,195,554 | 2021-11-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vogt-Koyanagi-Harada disease'. | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | BEVACIZUMAB, CARBOPLATIN, NIVOLUMAB, PEMETREXED | DrugsGivenReaction | CC BY-NC-ND | 34092725 | 20,195,554 | 2021-11-15 |
What was the administration route of drug 'BEVACIZUMAB'? | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 34092725 | 20,203,291 | 2021-11-15 |
What was the administration route of drug 'CARBOPLATIN'? | Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achie... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 34092725 | 20,203,291 | 2021-11-15 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.